title: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
abstract: New therapeutic alternatives are needed to improve outcomes in patients with androgen-independent prostate cancer (AIPC). For several years, researchers at the National Cancer Institute have been interested in elucidating the importance of angiogenesis in the pathogenesis of prostate cancer and in identifying inhibitors of this process. Thalidomide has been shown to inhibit the ability of tumors to recruit new blood vessels. In a recent phase II trial of thalidomide in AIPC, 28% of patients achieved a prostate-specific antigen (PSA) decrease of >40%. The taxane docetaxel also produces PSA and measurable disease responses when used as monotherapy or as a component of combination chemotherapy for AIPC. Thus, based on the single-agent activity of thalidomide and docetaxel, we initiated a randomized phase II study of weekly docetaxel with or without thalidomide, 200 mg at bedtime, in patients with chemotherapy-naive metastatic AIPC. Docetaxel, 30 mg/m(2) intravenously, was administered every 7 days for 3 weeks, followed by a 1-week rest period. Both regimens have been well tolerated among the first 59 treated patients, with a near absence of grade (3/4) myelosuppression. Fatigue, hyperglycemia, and pulmonary toxicity were seen in both groups. Thrombotic events have been seen in the combination arm. Thirty-five percent (6 of 17) of the patients receiving docetaxel alone and 53% (19 of 36) of those receiving docetaxel and thalidomide have had a PSA decrease of at least 50%. Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management.
authors.affiliation: Medicine Branch, Division of Clinical Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: W D
authors.initials: WD
authors.lastname: Figg
authors.forename: P
authors.initials: P
authors.lastname: Arlen
authors.forename: J
authors.initials: J
authors.lastname: Gulley
authors.forename: P
authors.initials: P
authors.lastname: Fernandez
authors.forename: M
authors.initials: M
authors.lastname: Noone
authors.forename: K
authors.initials: K
authors.lastname: Fedenko
authors.forename: M
authors.initials: M
authors.lastname: Hamilton
authors.forename: C
authors.initials: C
authors.lastname: Parker
authors.forename: E A
authors.initials: EA
authors.lastname: Kruger
authors.forename: J
authors.initials: J
authors.lastname: Pluda
authors.forename: W L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D013792:Thalidomide; D017239:Paclitaxel